NCT02583243View on ClinicalTrials.gov

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

CompletedOBSERVATIONAL
Enrollment

209

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Opioid-related DisordersHIV InfectionsHepatitis C, ChronicDepression
Interventions
BEHAVIORAL

MET/CBT based individualized counseling

Manualized counseling with the first four week being MET followed by 8 weeks of CBT

DRUG

Buprenorphine

Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.

Trial Locations (1)

06510

Yale University, New Haven

All Listed Sponsors
lead

Yale University

OTHER

NCT02583243 - Project BEST: Buprenorphine Entry Into Substance Abuse Treatment | Biotech Hunter | Biotech Hunter